title: Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer.
abstract: Japanese randomized trials showed that there was a significant impact on survival from stage I adenocarcinoma (AD) of the lung by adjuvant chemotherapy with uracil-tegaful after complete resection but there was no effect for patients with squamous cell carcinoma (SQ). The purpose of this study was to examine the correlation of tumor histology and clinical outcome of radiation therapy (RT) for stage I non-small-cell lung cancer (NSCLC) and to consider the necessity of adjuvant chemotherapy after RT for these patients. The subjects were 83 patients, 54 with SQ and 29 with AD; they had received definitive RT with the total dose ranging from 60 to 80 Gy with conventional fractionation at a daily dose of 2 Gy. The differences between SQ and AD with respect to survival and recurrence pattern were investigated. The 5-year overall survival and cause-specific survival rates were 26.5% and 49.1%, respectively. No difference in survival was observed between SQ and AD patients, and the recurrence rates were almost identical (44% for SQ and 45% for AD). However, the 5-year primary control rate of SQ was significantly poorer than that of AD (SQ: 61.5%; AD: 87.6%; p = 0.03). Conversely, the 5-year metastasis-free survival rate of SQ was significantly better than that of AD (SQ: 88.2%; AD: 53.0%; p = 0.005). The different failure pattern, according to tumor histology, indicates that taking into consideration the difference in their clinical behaviors would also be important for planning RT and surgery for early lung cancer.
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-Machi, Maebashi, Gunma, Japan. hisikawa@med.gunma-u.ac.jp
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Ishikawa
authors.forename: Yuko
authors.initials: Y
authors.lastname: Nakayama
authors.forename: Yoshizumi
authors.initials: Y
authors.lastname: Kitamoto
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nonaka
authors.forename: Hidemasa
authors.initials: H
authors.lastname: Kawamura
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Shirai
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Sakurai
authors.forename: Kazushige
authors.initials: K
authors.lastname: Hayakawa
authors.forename: Hideo
authors.initials: H
authors.lastname: Niibe
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology* / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006653:Histology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy; D012008:Recurrence; D015996:Survival Rate